Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma

Cancer Epidemiology

Volumn 39, Issue 2, 2015, Pages 182-188

  Goričar, Katja ^a   Kovač, Viljem ^b   Jazbec, Janez ^c   Zakotnik, Branko ^b   Lamovec, Janez ^b   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

Author keywords

Cisplatin; DNA repair; Osteosarcoma; Polymorphism

Indexed keywords

CISPLATIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE; METHOTREXATE; PROTEIN; PROTEIN NBN; RAD51 PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC3 PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMATOLOGIC DISEASE; HEREDITY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING; WIDE EXCISION; GENETIC POLYMORPHISM; GENETICS; YOUNG ADULT;

ADOLESCENT; ADULT; CISPLATIN; DNA REPAIR; FEMALE; GENETIC VARIATION; GLUTATHIONE TRANSFERASE; HUMANS; MALE; OSTEOSARCOMA; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926173801     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.12.009     Document Type: Article

References (32)

1. Ritter J., Bielack S.S. Osteosarcoma. Ann Oncol 2010, 21(Suppl. 7):vii320-vii325.
2. Ottaviani G., Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Rev 2009, 152:3-13.
3. Kuhelj D., Jereb B. Pediatric osteosarcoma: a 35-year experience in Slovenia. Pediatr Hematol Oncol 2005, 22:335-343.
4. Chou A.J., Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6:1075-1085.
5. Quartuccio N., Treglia G., Salsano M., Mattoli M.V., Muoio B., Piccardo A., et al. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 2013, 47:97-102.
6. Salinas-Souza C., Petrilli A.S., de Toledo S.R. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics 2010, 20:507-515.
7. Marsh S., McLeod H., Dolan E., Shukla S.J., Rabik C.A., Gong L., et al. Platinum pathway. Pharmacogenet Genomics 2009, 19:563-564.
8. Li X., Heyer W.D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008, 18:99-113.
9. Costa R.M., Chigancas V., Galhardo Rda S., Carvalho H., Menck C.F. The eukaryotic nucleotide excision repair pathway. Biochimie 2003, 85:1083-1099.
10. Erculj N., Kovac V., Hmeljak J., Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012, 23:961-967.
11. Yang Y., Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 2014, 35:2905-2921.
12. Hao T., Feng W., Zhang J., Sun Y.J., Wang G. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev 2012, 13:3821-3824.
13. Yang L.M., Li X.H., Bao C.F. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev 2012, 13:5883-5886.
14. Caronia D., Patino-Garcia A., Milne R.L., Zalacain-Diez M., Pita G., Alonso M.R., et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009, 9:347-353.
15. Biason P., Hattinger C.M., Innocenti F., Talamini R., Alberghini M., Scotlandi K., et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J 2012, 12:476-483.
16. Erculj N., Kovac V., Hmeljak J., Franko A., Dodic-Fikfak M., Dolzan V. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. J Thorac Oncol 2012, 7:1609-1617.
17. Shen X.Y., Lu F.Z., Wu Y., Zhao L.T., Lin Z.F. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PLoS ONE 2013, 8:e69553.
18. Xu J.L., Hu L.M., Huang M.D., Zhao W., Yin Y.M., Hu Z.B., et al. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac J Cancer Prev 2012, 13:851-856.
19. Goricar K., Erculj N., Zadel M., Dolzan V. Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. Radiol Oncol 2012, 46:46-53.
20. Goricar K., Kovac V., Jazbec J., Lamovec J., Dolzan V. Homologous recombination repair polymorphisms and the risk for osteosarcoma. J Med Biochem 2014, 10.2478/jomb-2014-0031.
21. Zhang S.L., Mao N.F., Sun J.Y., Shi Z.C., Wang B., Sun Y.J. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev 2012, 13:2705-2709.
22. Windsor R.E., Strauss S.J., Kallis C., Wood N.E., Whelan J.S. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2012, 118:1856-1867.
23. Jazbec J., Aplenc R., Dolzan V., Debeljak M., Jereb B. GST polymorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukemia 2003, 17:2540-2542.
24. Tregouet D.A., Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007, 23:1038-1039.
25. Erculj N., Kovac V., Hmeljak J., Franko A., Dodic-Fikfak M., Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012, 22:58-68.
26. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc B Met 1995, 57:289-300.
27. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
28. Spitz M.R., Wu X., Wang Y., Wang L.E., Shete S., Amos C.I., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61:1354-1357.
29. Teng J.W., Yang Z.M., Li J., Xu B. Predictive role of glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci 2013, 29:1182-1186.
30. Hmeljak J., Erculj N., Dolzan V., Kern I., Cor A. BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. J Cancer Res Clin Oncol 2011, 137:1641-1651.
31. Rae J.M., Cordero K.E., Scheys J.O., Lippman M.E., Flockhart D.A., Johnson M.D. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003, 13:501-507.
32. Hagleitner M.M., Coenen M.J., Jeuken J.W., Flucke U., Schreuder H.W., te Loo D.M., et al. Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. Pediatr Blood Cancer 2011, 56:35-38.